Filing Flows › DexCom (DXCM) › Q2 2026 › vs Q2 2025
DexCom (DXCM) Q2 2026 vs Q2 2025 (year over year)
DexCom's revenue rose $151M (+13%) from $1.2B in Q2 2025 to $1.3B in Q2 2026. Gross margin 63.4% against 59.5% (+3.9 pts).
DexCom, Q2 2026: revenue $1.3B (+13% year over year), operating margin 24.3%, net earnings $249M, operating cash flow $269M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Gross margin | 63.4% | 59.5% | +3.9 pts |
| Operating margin | 24.3% | 18.4% | +6.0 pts |
| Net margin | 19.0% | 15.5% | +3.5 pts |
| Free cash flow margin | 14.1% | 18.1% | -4.0 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $1.3B | $1.2B | $151M | +13% |
| Gross profit | $830M | $689M | $141M | +20% |
| Cost of revenue | $478M | $468M | $10.1M | +2% |
| Operating profit | $318M | $213M | $106M | +50% |
| Operating expenses | $512M | $476M | $35.5M | +7% |
| Pre-tax earnings | $318M | $241M | $76.4M | +32% |
| Research & development | $153M | $148M | $4.8M | +3% |
| SG&A | $359M | $328M | $30.7M | +9% |
| Net earnings | $249M | $180M | $69.3M | +39% |
| Income tax | $68.4M | $61.3M | $7.1M | +12% |
| Depreciation & amortization | $68.2M | $63.0M | $5.2M | +8% |
| Share-based compensation | $39.0M | $45.3M | −$6.3M | -14% |
| Working capital & other | $87.1M | −$14.9M | $102M | — |
| Operating cash flow | $269M | $303M | −$33.8M | -11% |
| Free cash flow (OCF − capex) | $184M | $209M | −$24.4M | -12% |
| Capital expenditures | $84.7M | $94.1M | −$9.4M | -10% |
Questions
How much did DexCom's revenue grow year over year in Q2 2026?
DexCom's revenue rose $151M (+13%) from $1.2B in Q2 2025 to $1.3B in Q2 2026. Gross margin 63.4% against 59.5% (+3.9 pts).